Németi Balázs, Gregus Zoltán
Department of Pharmacology and Pharmacotherapy, University of Pécs, Medical School, Szigeti út 12, H-7624 Pécs, Hungary.
Toxicol Sci. 2002 Nov;70(1):4-12. doi: 10.1093/toxsci/70.1.4.
After finding that rat liver mitochondria reduce arsenate (AsV) to the more toxic arsenite (AsIII), it was of interest to know if other cell fractions also carried out this process. Postmitochondrial supernatant (PMSN), isolated from rat liver, reduced AsV to AsIII only in the presence of a thiol. Dithiothreitol (DTT) supported the reduction much more effectively than glutathione. Separation of PMSN into microsome and cytosol revealed that the AsV reducing activity resided in the cytosol. AsV-like oxyanions, e.g., phosphate (P(i)) and vanadate, as well as mercurial thiol reagents inhibited the cytosolic AsV reducing activity, indicating the involvement of a P(i)-utilizing SH enzyme. On searching for a reduction partner, it was found unexpectedly that oxidized pyridine nucleotides (NAD(+) or NADP(+)), but not their reduced forms, increased AsIII formation. Some other purine nucleotide derivatives (e.g., AMP, GMP), but not pyrimidine nucleotides, also increased the rate 2-3-fold. Examination of the effect of nucleosides and nucleobases on AsV reduction yielded dramatic results: purine nucleosides (inosine or guanosine) increased the reduction 80-100-fold, whereas purine bases (hypoxanthine or guanine) decreased it 80-90%. Although the retentate obtained by ultrafiltration of cytosol was almost inactive, its AsV reductase activity could be regained by adding the filtrate or inosine or guanosine to the retentate, indicating that endogenous purine nucleosides were essential for AsV reduction by the cytosol. The hepatic cytosol of mice, hamsters, guinea pigs, and rabbits also exhibited AsV reductase activities in the presence of DTT, which were dramatically enhanced by inosine. Thus, the hepatic cytosol of all tested species can reduce AsV to AsIII. The reduction requires the presence of an appropriate thiol as well as a purine nucleoside (inosine or guanosine) and is inhibited by thiol reagents, the AsV analogue phosphate, and purine bases. Characterization of this AsV reductase activity led us to identification of a cytosolic AsV reductase, which is presented in the accompanying paper.
在发现大鼠肝脏线粒体可将砷酸盐(AsV)还原为毒性更强的亚砷酸盐(AsIII)后,人们很想知道其他细胞组分是否也能进行这一过程。从大鼠肝脏分离得到的线粒体后上清液(PMSN)仅在存在硫醇的情况下才将AsV还原为AsIII。二硫苏糖醇(DTT)比谷胱甘肽更有效地支持这种还原反应。将PMSN分离为微粒体和胞质溶胶后发现,AsV还原活性存在于胞质溶胶中。类似AsV的含氧阴离子,如磷酸盐(P(i))和钒酸盐,以及汞基硫醇试剂会抑制胞质溶胶中的AsV还原活性,这表明参与此过程的是一种利用P(i)的巯基酶。在寻找还原反应伙伴时,意外发现氧化型吡啶核苷酸(NAD(+)或NADP(+))而非其还原形式会增加AsIII的生成。其他一些嘌呤核苷酸衍生物(如AMP、GMP)而非嘧啶核苷酸也会使反应速率提高2 - 3倍。对核苷和碱基对AsV还原作用的研究产生了显著结果:嘌呤核苷(肌苷或鸟苷)使还原反应增加80 - 100倍,而嘌呤碱基(次黄嘌呤或鸟嘌呤)则使其降低80 - 90%。尽管通过对胞质溶胶进行超滤得到的截留物几乎没有活性,但通过向截留物中添加滤液或肌苷或鸟苷可恢复其AsV还原酶活性,这表明内源性嘌呤核苷对于胞质溶胶还原AsV至关重要。小鼠、仓鼠、豚鼠和兔子的肝脏胞质溶胶在DTT存在的情况下也表现出AsV还原酶活性,肌苷可显著增强这种活性。因此,所有受试物种的肝脏胞质溶胶都能将AsV还原为AsIII。这种还原反应需要存在合适的硫醇以及嘌呤核苷(肌苷或鸟苷),并会受到硫醇试剂、AsV类似物磷酸盐和嘌呤碱基的抑制。对这种AsV还原酶活性的特性研究使我们鉴定出一种胞质溶胶AsV还原酶,相关内容将在随附论文中阐述。